Literature DB >> 32964977

Downregulation of lncRNA CCHE1 inhibits cell proliferation, migration and invasion by suppressing MEK/ERK/c-MYC pathway in nasopharyngeal carcinoma.

X-J Meng1, J-C Wang, A-Q Wang, W-Q Xia.   

Abstract

OBJECTIVE: The current study was designed to investigate the functionality of lncRNA CCHE1 in nasopharyngeal carcinoma.
MATERIALS AND METHODS: MiRNA levels of lncRNA CCHE1 were examined by RT-qPCR. CCK8 assay and colony formation assay were together performed to detect cell proliferation viability. Furthermore, wound healing assay and transwell assay were respectively conducted to assess cell migration and invasion. In addition, proteins related to MEK/ERK/c-MYC pathway were detected by Western blot.
RESULTS: Elevated levels of CCHE1 were verified in NPC cell lines. Downregulation of CCHE1 significantly inhibited tumor growth and suppressed A549 cell proliferation, migration and invasion. MEK/ERK/c-MYC pathway was activated in nasopharyngeal carcinoma. Treatment of PD98059 (MEK inhibitor) or SCH772984 (ERK inhibitor) reversed the effects of CCHE1 on cell proliferation, migration and invasion in NPC.
CONCLUSIONS: The present study suggested that downregulation of lncRNA CCHE1 could inhibit cell proliferation, migration and invasion by suppressing MEK/ERK/c-MYC pathway in nasopharyngeal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32964977     DOI: 10.26355/eurrev_202009_22828

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  CDKN2B-AS1 promotes the proliferation, clone formation, and invasion of nasopharyngeal carcinoma cells by regulating miR-98-5p/E2F2 axis.

Authors:  Zhengwen Li; Xiaojing Cai; Wentao Zou; Jiaxiong Zhang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 2.  Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.

Authors:  Haihua Wang; Weiyuan Wang; Songqing Fan
Journal:  Int J Biol Sci       Date:  2022-03-28       Impact factor: 10.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.